| Description | LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC 50 of 8 for hCB2, and a pK i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors. LEI-101 has therapeutic potential in diseases that are associated with inflammation and/or oxidative stress, including kidney disease [1] [2]. |
| molecular weight | 472.53 |
| Molecular formula | C23H25FN4O4S |
| CAS | 1228660-00-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15. PubMed PMID: 26398481; PubMed Central PMCID: PMC4728411. |